Analysts Expect Syros Pharmaceuticals Inc (SYRS) Will Announce Earnings of -$0.50 Per Share

Equities analysts predict that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will report ($0.50) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.53). Syros Pharmaceuticals posted earnings per share of ($0.58) during the same quarter last year, which would suggest a positive year-over-year growth rate of 13.8%. The company is expected to announce its next quarterly earnings report on Monday, March 11th.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($1.87) per share for the current year, with EPS estimates ranging from ($1.90) to ($1.85). For the next year, analysts anticipate that the firm will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.11) to ($1.80). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that cover Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Thursday, November 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.02). The business had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $0.72 million.

A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 6th. Roth Capital set a $14.00 price target on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday. Wedbush restated an “outperform” rating and issued a $13.00 price target on shares of Syros Pharmaceuticals in a research note on Monday. HC Wainwright restated a “hold” rating and issued a $10.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday, August 8th. Finally, JMP Securities set a $33.00 price target on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 1st. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $19.29.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its position in Syros Pharmaceuticals by 10.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 77,654 shares of the company’s stock worth $925,000 after buying an additional 7,062 shares during the period. MetLife Investment Advisors LLC boosted its position in Syros Pharmaceuticals by 55.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 20,338 shares of the company’s stock worth $242,000 after buying an additional 7,230 shares during the period. JPMorgan Chase & Co. boosted its position in Syros Pharmaceuticals by 2.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 369,959 shares of the company’s stock worth $4,406,000 after buying an additional 8,286 shares during the period. Rhumbline Advisers boosted its position in Syros Pharmaceuticals by 87.6% during the 2nd quarter. Rhumbline Advisers now owns 22,472 shares of the company’s stock worth $229,000 after buying an additional 10,494 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in Syros Pharmaceuticals during the 2nd quarter worth approximately $119,000. Institutional investors own 61.26% of the company’s stock.

Syros Pharmaceuticals stock traded up $0.91 during trading hours on Friday, reaching $7.72. 3,035 shares of the stock were exchanged, compared to its average volume of 84,765. Syros Pharmaceuticals has a twelve month low of $6.25 and a twelve month high of $15.88. The company has a market capitalization of $229.19 million, a price-to-earnings ratio of -3.51 and a beta of 0.79.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

See Also: Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit